HR positive

News alerts, weekly reports and conference planners

Entrez ID:

2099; 5241

Related biomarkers:

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3d	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) abemaciclib Sensitive : A1 ASCO 2023 - 3d	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days abemaciclib Sensitive : A1 ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) G1T38 Sensitive : B ASCO 2023 - 3d	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days G1T38 Sensitive : B ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days (New C3) dalpiciclib Sensitive : B ASCO 2023 - 3d	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days dalpiciclib Sensitive : B ASCO 2023 - 3 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week (New C3) ribociclib Sensitive : A1 J Clin Oncol - 1wk	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week ribociclib Sensitive : A1 J Clin Oncol - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week (New C3) U3-1402 Sensitive : C2 Ann Oncol - 1wk	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week U3-1402 Sensitive : C2 Ann Oncol - 1 week - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2wk	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3wk	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) AZD5363 Sensitive : B ESMO-BC 2023 - 3wk	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks AZD5363 Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) neratinib Sensitive : A1 ESMO-BC 2023 - 3wk	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks neratinib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) palbociclib Sensitive : A1 ESMO-BC 2023 - 3wk	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks palbociclib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) capecitabine Sensitive : A2 ESMO-BC 2023 - 3wk	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks capecitabine Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	Leiomyosarcoma	HR positive	Leiomyosarcoma	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks (New C3) nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3wk	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3 weeks - (New C3)
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2	HER2 inhibitor Sensitive: A2 - Guideline HER2 inhibitor Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	HER2 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline HER2 inhibitor + Aromatase inhibitor Sensitive : A2	HER2 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline HER2 inhibitor + Aromatase inhibitor Sensitive : A2
HR positive	Male Breast Cancer	HR positive	Male Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
HR positive	Male Breast Cancer	HR positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	estradiol Sensitive: A2 - Guideline estradiol Sensitive : A2	estradiol Sensitive: A2 - Guideline estradiol Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive : A2	CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	vinorelbine Sensitive: A2 - Guideline vinorelbine Sensitive : A2	vinorelbine Sensitive: A2 - Guideline vinorelbine Sensitive : A2
HR positive	Soft Tissue Sarcoma	HR positive	Soft Tissue Sarcoma	GnRH agonist Sensitive: A2 - Guideline GnRH agonist Sensitive : A2	GnRH agonist Sensitive: A2 - Guideline GnRH agonist Sensitive : A2
HR positive	Soft Tissue Sarcoma	HR positive	Soft Tissue Sarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2

HR positive

Associations